Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | PIM1 | P11309 | 4/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23950604 | 1.00 | CLK1 (0.36) | CLK1DYRK1AHSP90AA1KCNH2PIM1 | |
| SCHEMBL23951140 | 0.91 | CYP11B1 (0.39) | CLK1DYRK1AKCNH2PIM1 | |
| SCHEMBL23950974 | 0.91 | CLK1 (0.37) | CLK1DYRK1AHSP90AA1KCNH2PIM1 | |
| SCHEMBL23950972 | 0.91 | CLK1 (0.37) | CLK1DYRK1AHSP90AA1KCNH2PIM1 | |
| SCHEMBL23925575 | 0.91 | CYP11B1 (0.39) | CLK1DYRK1AKCNH2PIM1 | |
| SCHEMBL23925713 | 0.91 | CYP11B1 (0.39) | CLK1DYRK1AKCNH2PIM1 | |
| SCHEMBL23390480 | 0.89 | CLK1 (0.39) | CLK1DYRK1AHSP90AA1KCNH2PIM1 | |
| SCHEMBL23925582 | 0.88 | CYP2A6 (0.39) | CLK1DYRK1AKCNH2PIM1PIK3CA | |
| SCHEMBL23950769 | 0.88 | CYP2A6 (0.39) | CLK1DYRK1AKCNH2PIM1PIK3CA | |
| SCHEMBL30101964 | 0.88 | CYP2A6 (0.39) | CLK1DYRK1AKCNH2PIM1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115443276-B | Pyridopyrimidinone derivatives and their use as arene receptor modulators | 东亚ST株式会社 | 2025-04-18 | — | — | CN | claimed |
| US-20230147257-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | DONG-A ST CO., LTD. (KR) | 2023-05-11 | — | — | US | claimed |
| EP-4136088-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | Dong-A ST Co., Ltd. (KR) | 2023-02-22 | — | — | EP | claimed |
| WO-2021210970-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | DONG-A ST CO., LTD. (KR) | 2021-10-21 | — | — | WO | claimed |
| CN-115443276-B | Pyridopyrimidinone derivatives and their use as arene receptor modulators | 东亚ST株式会社 | 2025-04-18 | — | — | CN | disclosed |
| US-20230147257-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | DONG-A ST CO., LTD. (KR) | 2023-05-11 | — | — | US | disclosed |
| US-20230147257-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | DONG-A ST CO., LTD. (KR) | 2023-05-11 | — | — | US | disclosed |
| US-20230147257-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | DONG-A ST CO., LTD. (KR) | 2023-05-11 | — | — | US | disclosed |
| EP-4136088-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | Dong-A ST Co., Ltd. (KR) | 2023-02-22 | — | — | EP | disclosed |
| CN-115443276-A | Pyridopyrimidinone derivatives and their use as modulators of aromatic hydrocarbon receptors | 东亚ST株式会社 | 2022-12-06 | — | — | CN | disclosed |
| WO-2021210970-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | DONG-A ST CO., LTD. (KR) | 2021-10-21 | — | — | WO | disclosed |
| WO-2021210970-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | DONG-A ST CO., LTD. (KR) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230147257-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | AHR, ARNT, AIPL1 | CLK1 4122/4885DYRK1A 2368/4885HSP90AA1 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.